DCM
ABEO icon

DAFNA Capital Management’s Abeona Therapeutics ABEO Stock Holding History

DAFNA Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,701
Closed -$338K – 76
2017
Q1 		$338K Sell
2,701
-371
-12% -$47.8K 0.29% 60
2016
Q4 		$372K Buy
+3,072
New +$481K 0.33% 56
2016
Q3 		– Sell
-7,273
Closed -$429K – 76
2016
Q2 		$429K Hold
7,273
– – 0.34% 63
2016
Q1 		$465K Hold
7,273
– – 0.4% 66
2015
Q4 		$611K Hold
7,273
– – 0.54% 47
2015
Q3 		$736K Buy
+7,273
New +$965K 0.73% 38

Other funds holding ABEO

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

DAFNA Capital Management's ABEO Position: Q2 2017 in Review

DAFNA Capital Management sold out of Abeona Therapeutics (ABEO) in Q2 2017, closing a stake of 2,701 shares — an estimated $338K sold.

DAFNA Capital Management first reported a position in ABEO in Q3 2015 and held it in 6 quarters. The position peaked at $736K in Q3 2015. 70 funds tracked by Wall St. Rank hold ABEO as of Q2 2017.

  • DAFNA Capital Management reported no remaining Abeona Therapeutics position as of Q2 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 2,701 Abeona Therapeutics shares in Q2 2017, an estimated $338K.
  • DAFNA Capital Management first reported a position in Abeona Therapeutics in Q3 2015 and held it in 6 quarters.
  • DAFNA Capital Management's Abeona Therapeutics position peaked at $736K in Q3 2015.
  • 70 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2017.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.